Hall Laurie J Trustee boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,785 shares of the company’s stock after buying an additional 1,287 shares during the quarter. Johnson & Johnson accounts for approximately 3.5% of Hall Laurie J Trustee’s portfolio, making the stock its 5th largest holding. Hall Laurie J Trustee’s holdings in Johnson & Johnson were worth $6,163,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Financial Gravity Wealth Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $105,000. WP Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $108,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $117,000. Live Your Vision LLC grew its position in shares of Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after purchasing an additional 502 shares during the last quarter. Finally, Cognios Beta Neutral Large Cap Fund LP acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $203,000. Institutional investors own 66.06% of the company’s stock.

Shares of JNJ opened at $144.50 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The company has a market cap of $390.68 billion, a P/E ratio of 19.79, a PEG ratio of 2.28 and a beta of 0.58. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.90 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 8.16 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.49%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.

Several research firms have recently commented on JNJ. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Raymond James increased their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Finally, Citigroup increased their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $142.54.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joaquin Duato sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now directly owns 112,848 shares in the company, valued at approximately $16,290,737.28. The disclosure for this sale can be found here. Insiders have sold 85,340 shares of company stock worth $11,992,396 in the last three months. Insiders own 0.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Hall Laurie J Trustee Raises Holdings in Johnson & Johnson (JNJ)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/11/16/hall-laurie-j-trustee-raises-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Find a Trading Strategy That Works

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.